Vanguard Asset Management
ORKA

Vanguard Asset Management’s Oruka Therapeutics ORKA Stock Holding History

Vanguard Asset Management’s Portfolio ORKA Stock Details ORKA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.05M Buy
21,569
+6,963
+48% +$464K ﹤0.01% 1538
2026
Q1 		$716K Buy
+14,606
New +$508K ﹤0.01% 1934

Other funds holding ORKA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Vanguard Asset Management's ORKA Position: Q2 2026 in Review

Vanguard Asset Management increased its Oruka Therapeutics (ORKA) stake by 48% in Q2 2026, buying an estimated $464K and bringing the position to 21,569 shares worth $2.05M. The position accounts for ﹤0.01% of the portfolio, ranked #1538.

Vanguard Asset Management first reported a position in ORKA in Q1 2026 and has held it in 2 quarters since. 237 funds tracked by Wall St. Rank hold ORKA as of Q2 2026.

  • Vanguard Asset Management held 21,569 shares of Oruka Therapeutics worth $2.05M as of Q2 2026.
  • Vanguard Asset Management bought 6,963 Oruka Therapeutics shares in Q2 2026, an estimated $464K.
  • Oruka Therapeutics made up ﹤0.01% of Vanguard Asset Management's portfolio in Q2 2026, its #1538 holding.
  • Vanguard Asset Management first reported a position in Oruka Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 237 funds tracked by Wall St. Rank held Oruka Therapeutics as of Q2 2026.

Based on Vanguard Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.